U.S. Markets closed

Marrone Bio Innovations, Inc. (MBII)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.40000.0000 (0.00%)
At close: 4:00PM EDT
1.4000 0.00 (0.00%)
After hours: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4000
Open1.3900
Bid1.3700 x 2200
Ask1.4000 x 1100
Day's Range1.3800 - 1.4400
52 Week Range1.0600 - 2.9000
Volume92,554
Avg. Volume461,152
Market Cap245.43M
Beta (5Y Monthly)0.15
PE Ratio (TTM)N/A
EPS (TTM)-0.1050
Earnings DateAug 09, 2021 - Aug 13, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.23
  • Rizobacter and Marrone Bio Innovations Expand Strategic Alliance to Supply  Novel Seed Treatment in Brazil
    GlobeNewswire

    Rizobacter and Marrone Bio Innovations Expand Strategic Alliance to Supply Novel Seed Treatment in Brazil

    PERGAMINO, Argentina and DAVIS, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Rizobacter -- a subsidiary of Bioceres Crop Solutions Corp. (NYSE: BIOX) and a global leader in sustainable solutions for agriculture -- and Marrone Bio (NASDAQ: MBII) (MBI) -- an international leader in sustainable bioprotection and plant health solutions -- today announced that Rizonema™, a biological seed treatment for nematodes and soil dwelling insects, will be offered for use in row crops in Brazil through an expande

  • Where Do Hedge Funds Stand On Marrone Bio Innovations Inc (MBII)?
    Insider Monkey

    Where Do Hedge Funds Stand On Marrone Bio Innovations Inc (MBII)?

    After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of March 31st. The results of that effort will be put on display in this article, as […]

  • GlobeNewswire

    180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors

    MENLO PARK, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has appointed Pamela Marrone, PhD, and Frank Knuettel II, MBA, to its Board of Directors (“Board”) effective upon the earlier of (a) the business day following the filing of the 2020 Form 10-K A